Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR ...

BL-M11D1, a CD33-binding antibody-drug conjugate, is being evaluated for the treatment of patients with acute myeloid ...

Therapy-related acute promyelocytic leukemia (t-APL) is rare and often linked to previous treatment with alkylating agents or topoisomerase II inhibitors. This report describes three cases of t-APL ...

Scientists have identified a promising new target for cancer treatment by activating a DNA repair enzyme called TDP1, ...

01 英国牛津大学拉德克利夫医院的研究团队在Cell杂志上发表了一篇论文，发现TEX264介导的核吞噬作用在维持基因组稳定性和细胞存活中发挥关键作用。

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China for the ...

The breakthrough research was conducted by scientists at the Indian Association for the Cultivation of Science (IACS), ...

In a promising development for cancer treatment, researchers have pinpointed a new target by activating a DNA repair enzyme ...

After hours: October 11 at 5:50 PM EDT Loading Chart for ZYME ...

Expert Rev Anti Infect Ther. 2013;11(3):297-308.

The triple-negative breast cancer market dynamics are expected to change in the coming years with the upcoming availability ...